Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Pyr3 mg Finally we show that the
2024-09-12

Finally, we show that the optimal corporate tax rate is strictly positive, balancing the increase in tax revenues against the loss in consumer surplus due to higher prices and fewer firms (products). This result is related to the well-known “excessive entry theorem” that shows, for a large class of
-
br Funding br Introduction l Dihydroxyphenylalanine l DOPA i
2024-09-12

Funding Introduction l-3,4-Dihydroxyphenylalanine (l-DOPA) is the gold-standard treatment for the motor symptoms of Parkinson's disease (PD); however, its chronic use induces severe motor complications that eventually limit its long-term efficacy (Bastide et al., 2015). The most disabling side
-
Because LTs are proved to mediate
2024-09-12

Because LTs are proved to mediate multiple biological and pathological responses in various disease states, the 5-LO biosynthetic pathway producing LTs from AA have been the target of drug discovery efforts for over two decades. As observed from literature, a pile of research efforts has been direct
-
Steroidal CYP inhibitors can further be classified based
2024-09-12

Steroidal CYP17 inhibitors can further be classified based on their mode of action, namely as mechanism-based inhibitors and type I and type II competitive inhibitors [129]. Recent studies investigated other biological targets than CYP17, and some new compounds have shown interesting dual activity a
-
hesperetin br Acknowledgement This work was funded by NIH NI
2024-09-12

Acknowledgement This work was funded by NIH/NINDS grant number NS080967 to C. Waites. Introduction Macro-autophagy also called autophagy is a conserved pathway for the lysosomal degradation and recycling of intracellular materials. It is instrumental for the homeostasis of cells and tissues a
-
The GRAVY value for a protein is calculated as
2024-09-12

The GRAVY value for a protein is calculated as the sum of hydropathy values of all the amino acids, divided by the number of residues in the sequence (Kyte and Doolittle, 1982). According to Kyte and Doolittle (1982) integral membrane proteins typically have higher GRAVY scores than do globular prot
-
CK is considered a central controller
2024-09-12

CK is considered a central controller of cellular energy homeostasis that catalyzes the reversible transfer of a phosphoryl group from ATP to adenosine diphosphate (ADP) and creatine to produce PCr [5]. This enzyme builds up a large pool of rapidly diffusing PCr for temporal and spatial buffering of
-
When skeletal muscle ages there is an increase
2024-09-12

When skeletal muscle ages, there is an increase in frailty, which is coincident with a decrease in muscle mass and function—this condition is called sarcopenia (Cruz-Jentoft et al., 2010). It has been shown that one of the major pathways downregulated at the onset of sarcopenia is the mitochondrial
-
Hypoxia of the adipose tissue
2024-09-12

Hypoxia of the adipose tissue is a key step in the inflammatory response linked to obesity and contributes to accelerated tumor progression in the obese population (Rosenow et al., 2013). Intermittent hypoxia exposure induces a 2.2-fold increase in the infiltration of tumor-associated macrophages an
-
The PDZ domains of DLG interact with tumor suppressor
2024-09-11

The PDZ domains of DLG interact with tumor suppressor proteins, APC and PTEN, as well as with several viral oncoproteins such as the E6 protein present in oncogenic human papillomavirus (reviewed in [177]). It has been reported that overexpression of DLG in fibroblasts impairs the events in the G0/G
-
EPSP analogs were retrieved from PubChem database and
2024-09-11

EPSP analogs were retrieved from PubChem database and docking procedure yielded about eight best binding analogs (Fig. 10). The selected molecules were further assessed for their theoretical Ki values using AUTODOCK software version 4. The predicted binding efficiency of retrieved analogs was estima
-
Previous research showed that combination of chitosan and ce
2024-09-11

Previous research showed that combination of chitosan and Reparixin nanocrystals (CNCs) can produce coating films with superior properties (Naseri, Mathew, Girandon, Fröhlich, & Oksman, 2015). CNCs are crystalline nanometer sized rod-like particles. It has been demonstrated that antimicrobial activ
-
The electrokinetic remediation technique is carried out with
2024-09-11

The electrokinetic remediation technique is carried out with a low-level direct current, and the pollutants in soil can be transported and removed by the electric field [19]. This works well even in soil with low permeability via electro-osmotic flow and electro-migration [20]. The electrokinetic pr
-
Pathological angiogenesis occurs when an imbalance of endoge
2024-09-11

Pathological angiogenesis occurs when an imbalance of endogenous proangiogenic and antiangiogenic factors occurs. Although the focus of angiogenesis-related drug development has been geared to the discovery of antiangiogenic compounds for use in pathologies where excessive angiogenesis occurs (canc
-
CUDC-101 br Development of lorlatinib from crizotinib
2024-09-11

Development of lorlatinib from crizotinib (1) to a clinical candidate (6) Xalkori (1, PF-02341066, crizotinib), was the first-in-class ALK inhibitor approved by the Unites States Food and Drug Administration (FDA) in 2011 as a first-line treatment for ALK+- NSCLC patients. This section describes
15508 records 98/1034 page Previous Next First page 上5页 96979899100 下5页 Last page